StreetAlpha.app
Home › Stocks › CBIO

Crescent Biopharma, Inc. (CBIO)

$13.00
▲ +0.70%
LAST CLOSE · NOV 20

Crescent Biopharma develops cancer treatments, including antibody and antibody drug conjugate candidates still in clinical trials. It last closed at $13.00 on Nov 20, up 0.70% on the day. The next earnings report for CBIO is expected around Thu, Feb 25, 2027. Over its last 8 reports the stock moved an average of 3.0% the session after earnings. Over the last 12 months CBIO insiders bought $30.6M of stock on the open market and sold $1.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is CBIO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CBIO.

Key Stats

Last 12 months
Results
Revenue
$15.0M
Net income
−$178.2M
−1188.3% margin
Free cash flow
−$82.4M
−549.5% margin
Operating margin
−1216.6%
−$182.5M operating income
Valuation
Market cap
$505.6M
38.9M shares
P/E
–
Price to sales
33.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$289.4M
At Sep 30
Shareholder equity
$274.3M
Shares outstanding
38.9M
At Nov 11
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.2M$1.2MFY2021FY2022: $75K$75KFY2022FY2023: $10K$10KFY2023FY2025: $10.8M$10.8MFY2025

From CBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
—
Quarter ended Sep 2026
Year ago EPS
—
Same quarter last year
Revenue
$3.1M
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.11Dec '24Mar 2025: -$0.04Mar '25Latest -$0.04
Revenue by quarter
Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $10.8MDec '25Mar 2026: $1.0MMar '26Jun 2026: $0Jun '26Sep 2026: $3.1MSep '26Latest $3.1M
How CBIO moved after its last 8 reports
Average move the session after a report ±3.0%
Nov 12, 2026After the close−1.5%
Jul 14, 2026After the close+2.4%
Apr 29, 2026After the close+6.8%
Feb 26, 2026Time not announced−1.2%
Nov 6, 2025Time not announced+5.4%
Jul 31, 2025Time not announced−1.4%
Jun 18, 2025After the close+2.6%
Aug 2, 2023Time not announced−3.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CBIOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CBIO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CBIO

Technical Analysis

CBIO · as of the Nov 20 close · updated each morning
Downtrend

The stock is 3% below its 20 day and 8% below its 50 day average. It is 23% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 45). The nearest support is the Pivot at $12.94, and the nearest resistance the Pivot R1 at $13.36.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 8.5%/day
Key levels
$27.4152 week high+110.8%
$16.04200 day average+23.4%
$15.52100 day average+19.4%
$14.1050 day average+8.5%
$13.81Swing high (Oct 21)+6.2%
$13.4520 day average+3.5%
$13.36Pivot R1+2.8%
$13.00Last close
$12.94Pivot−0.5%
$12.68Swing low (Nov 2)−2.5%
$12.59Pivot S1−3.2%
$8.7252 week low−32.9%
Indicators
RSI (14)45.04Middle of its rangeNeutral
MACD-0.24Below its signal lineBearish
Stochastic17.4Near the bottom of its rangeOversold
ADX (14)11.3No clear trend
Williams %R-74.5Oversold below −80, overbought above −20Neutral
CCI (20)-78.0Oversold below −100, overbought above 100Neutral
Rate of change−4.0%Change over 10 sessionsBearish
ATR (14)$1.10Typical daily range, 8.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CBIO

What happened before

See how CBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CBIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CBIOHow many large options trades hit CBIO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲81 buying vs 27 selling
  • ▲Held by funds +28.4 pts
  • ▲Funds holding +24
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10682+29.3%
In funds' top 10330.0%
Held by funds104.5%76.1%+28.4 pts
New / increased37 / 4432 / 17+65.3%
Reduced / sold out13 / 1415 / 13−3.6%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CBIO Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$30.6M2 buys · 2 insiders
Sold$1.5M14 sales · 7 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 bought $18.2M2026-06 sold $1.2M2026-07 bought $12.4M2026-09 sold $286KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 18Jonathan McNeillPresident and COOSale plan4,570$16.90$77K
Sep 18Joshua T BrummCEOSale plan9,447$16.91$160K
Sep 16Barbara Harlin BisphamSee RemarksSale plan620$17.90$11K
Sep 16Richard William ScalzoCFOSale plan568$17.90$10K
Sep 16Ellie Eunkyung ImChief Medical OfficerSale plan623$17.90$11K
Sep 16Jan PinkasChief Scientific OfficerSale plan658$17.90$12K
Every insider buy and sale for CBIO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CBIO insider trades →

From SEC Form 4 filings by CBIO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CBIO is in one of them and how their past CBIO trades turned out.

CBIO in the AI portfolios
Loading…

CBIO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CBIO in an article yet. Here's the latest on the wider market.

CBIO in the news

About Crescent Biopharma

Crescent Biopharma is a biotechnology company based in Waltham, Massachusetts, that develops treatments for cancer. Its lead candidate, CR-001, is an antibody designed to bind two proteins, PD-1 and VEGF, that affect how tumors grow and how the immune system responds. The company is also developing antibody drug conjugates, which are designed to deliver a toxin directly to cancer cells. Its candidates are still in clinical trials and are not yet approved for sale.

Headquarters
Waltham, MA